Recovering erections grabs the attention of most men and their doctors after prostate cancer treatment. A new study redirects ...

In an effort to find new treatments for castrate-resistant prostate cancer, a TTUHSC research team led by Srinivas Nandana, ...

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Although the role of radiation therapy is well established in this setting, the role of radical prostatectomy in treating men with de novo oligometastatic prostate cancer has not been well defined.

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug ...